 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Drug:
|
ABT925
|
|
Clinical Trial ID:
|
NCT00412620
|
|
Mode of action:
|
D3-R antagonist
|
|
Phase:
|
POC Failed
|
|
Company:
|
Abbott
|
|
Note:
|
Insufficient target engagement
|
Redden L, Rendenbach-Mueller B, Abi-Saab WM, Katz
DA, Goenjian A, Robieson WZ, Wang Y, Goss SL, Greco N,
Saltarelli MD. A double-blind, randomized,
placebo-controlled study of the dopamine D3 receptor
antagonist ABT-925 in patients with acute schizophrenia. J
Clin Psychopharmacol . 2011 Apr ; 31(2):221-5. Abstract
Geneste H, Amberg W, Backfisch G, Beyerbach A, Braje WM,
Delzer J, Haupt A, Hutchins CW, King LL, Sauer DR, Unger L,
Wernet W. Synthesis and SAR of highly potent and selective
dopamine D3-receptor antagonists: variations on the
1H-pyrimidin-2-one theme. Bioorg Med Chem Lett . 2006 Apr 1
; 16(7):1934-7. Abstract
|
|
|
|
|
Text Size 
See our most recent Schizophrenia Bulletin theme Webinar: